SCHEMBL16850619

SCHEMBL16850619

CCC(C)[C@@H](CO)n1cc(C(=O)O)c(=O)c2cc(Cc3cccc(Cl)c3F)ccc21

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ METTL3 Q86U44 1/20 0.63
▸ CFD P00746 2/20 0.35
▸ GAA P10253 1/20 0.34
▸ HTT P42858 1/20 0.34
▸ TOP1 P11387 4/20 0.34
▸ MAPT P10636 3/20 0.34
▸ KDM4E B2RXH2 3/20 0.34
▸ TP53 P04637 2/20 0.33
▸ POLB P06746 1/20 0.33
▸ ALDH1A1 P00352 2/20 0.33
▸ HPGD P15428 2/20 0.33
▸ HSD17B10 Q99714 2/20 0.33
▸ CHRM1 P11229 1/20 0.33
▸ TSHR P16473 1/20 0.33
▸ RAB9A P51151 1/20 0.33
▸ CYP1A2 P05177 1/20 0.33
▸ CYP2D6 P10635 1/20 0.33
▸ APEX1 P27695 1/20 0.33
▸ TDP1 Q9NUW8 1/20 0.33
▸ PIK3CD O00329 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1078870 1.00 METTL3 (0.63) METTL3CFDGAAHTTTOP1
SCHEMBL1078873 1.00 METTL3 (0.63) METTL3CFDGAAHTTTOP1
SCHEMBL1045282 0.92 METTL3 (0.73) METTL3CFDGAAHTTTOP1
SCHEMBL1045281 0.92 METTL3 (0.73) METTL3CFDGAAHTTTOP1
SCHEMBL16823349 0.90 METTL3 (0.58) METTL3CFDGAAHTTTOP1
SCHEMBL3243216 0.89 METTL3 (0.54) METTL3CFDMAPTTP53POLB
SCHEMBL4370961 0.89 METTL3 (0.67) METTL3CFDGAAHTTTOP1
SCHEMBL1045788 0.89 METTL3 (0.57) METTL3CFDGAAHTTTOP1
SCHEMBL1045787 0.89 METTL3 (0.57) METTL3CFDGAAHTTTOP1
SCHEMBL1041876 0.89 METTL3 (0.63) METTL3CFDGAAHTTTOP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230190730-A1 4-OXOQUINOLINE COMPOUND AND USE THEREOF AS PHARMACEUTICAL AGENT JAPAN TOBACCO INC. (JP) 2023-06-22 — — US disclosed
US-20230190730-A1 4-OXOQUINOLINE COMPOUND AND USE THEREOF AS PHARMACEUTICAL AGENT JAPAN TOBACCO INC. (JP) 2023-06-22 — — US disclosed
US-20150174117-A1 4-OXOQUINOLINE COMPOUND AND USE THEREOF AS PHARMACEUTICAL AGENT JAPAN TOBACCO INC. 2015-06-25 — — US disclosed
US-20150174117-A1 4-OXOQUINOLINE COMPOUND AND USE THEREOF AS PHARMACEUTICAL AGENT JAPAN TOBACCO INC. 2015-06-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150174117-A1 4-OXOQUINOLINE COMPOUND AND USE THEREOF AS PHARMACEUTICAL AGENT IMPDH1, CDKL4, IMPDH2 METTL3 1398/4885CFD 4186/4885GAA 329/4885
US-20230190730-A1 4-OXOQUINOLINE COMPOUND AND USE THEREOF AS PHARMACEUTICAL AGENT IMPDH1, IMPDH2, DNTT METTL3 1258/4885CFD 4354/4885GAA 331/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback